BRNS
Barinthus Biotherapeutics plc
NASDAQ: BRNS · HEALTHCARE · BIOTECHNOLOGY
$0.60
-1.66% today
Updated 2026-04-29
Market cap
$26.23M
P/E ratio
—
P/S ratio
2.17x
EPS (TTM)
$-1.64
Dividend yield
—
52W range
$1 – $3
Volume
0.0M
Barinthus Biotherapeutics plc (BRNS) Financial statements
SEC filings — annual and quarterly data.
Income statement — annual
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $6.85M | $4.82M | $268000.00 | $44.70M | $802000.00 | $14.97M | $0.00 |
| Revenue growth (YoY) | — | -29.6% | -94.4% | +16580.2% | -98.2% | +1766.5% | -100.0% |
| Cost of revenue | $29.84M | $14.39M | — | — | $3108.00 | $5.80M | $5.86M |
| Gross profit | $-23.00M | $-9.57M | $268000.00 | $44.70M | $802000.00 | $14.97M | $-5.86M |
| Gross margin | -336.0% | -198.4% | 100.0% | 100.0% | 100.0% | 100.0% | — |
| R&D | $29.84M | $14.39M | $16.37M | $41.11M | $41.41M | $38.25M | $25.56M |
| SG&A | $2.67M | $10.48M | $25.12M | $6.39M | $39.84M | $29.67M | $40.83M |
| Operating income | $-25.66M | $-20.05M | $-45.22M | $-4.04M | $-83.91M | $-67.97M | $-54.19M |
| Operating margin | -374.9% | -415.8% | -16873.5% | -9.0% | -10463.1% | -454.1% | — |
| EBITDA | $-22.52M | $-16.56M | $-47.87M | $5.19M | $-71.06M | $-55.37M | $-48.34M |
| EBITDA margin | -329.0% | -343.5% | -17861.9% | 11.6% | -8861.0% | -369.9% | — |
| EBIT | $-22.69M | $-16.77M | $-48.47M | $869000.00 | $-76.49M | $-61.17M | $-54.18M |
| Interest expense | $133299.00 | $3.60M | $2.67M | $19000.00 | $28000.00 | $53000.00 | $51119.00 |
| Income tax | — | — | — | — | — | — | — |
| Effective tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | $-20.73M | $-17.71M | $-50.87M | $5.34M | $-73.35M | $-61.07M | $-66.43M |
| Net income growth (YoY) | — | +14.6% | -187.3% | +110.5% | -1473.0% | +16.7% | -8.8% |
| Profit margin | -302.8% | -367.3% | -18979.5% | 11.9% | -9145.5% | -408.0% | — |